Compare WHF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHF | SCLX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2M | 139.3M |
| IPO Year | 2012 | N/A |
| Metric | WHF | SCLX |
|---|---|---|
| Price | $7.02 | $13.82 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 235.7K | 73.1K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | ★ 26.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $76,339,000.00 | $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $15.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.39 | $3.60 |
| 52 Week High | $11.31 | $34.27 |
| Indicator | WHF | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.50 | 34.28 |
| Support Level | $6.76 | $18.34 |
| Resistance Level | $7.08 | $20.62 |
| Average True Range (ATR) | 0.20 | 1.04 |
| MACD | -0.08 | -0.46 |
| Stochastic Oscillator | 24.07 | 13.40 |
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.